Drug intelligence / Profile preview

BI 144807

Development stage: Phase 2
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BI 144807 is an orally administered small molecule drug initially developed by Boehringer Ingelheim for the treatment of wet age-related macular degeneration (wAMD), asthma, and allergic rhinitis. It acts as a CCR3 antagonist and was later known as ALK4290 and AKST4290 in subsequent development. The drug has been evaluated in phase II clinical trials for neovascular (wet) age-related macular degeneration, where it demonstrated improvement in best-corrected visual acuity with a favorable safety profile. Its mechanism of action involves antagonism of the C-C chemokine receptor type 3 (CCR3), which is implicated in inflammatory processes relevant to its target indications[1][3][7].

Other names: lazucirnon

Targets

CCR3 (C-C chemokine receptor type 3)

Beyond the preview

Go deeper on BI 144807.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 144807.

Explore the full profile